Wednesday, Jan 14, 2026 · SEC filings
What the smart money revealed on Jan 14
270 insider filings came in. We hid 48 planned (10b5-1) sellers and 158 people whose filings were routine, like grants and tax withholding.
Aktis Oncology (AKTS) Director Todd Foley bought $4.19M
232,870 shares on the open market. Not a grant or an option exercise.
Strive (ASST) CEO Matthew Cole bought $460K
500,000 shares on the open market. Not a grant or an option exercise.
General American Investors (GAM) VP Administration/CCO/PFO Eugene Stark bought $99.9K
4,000 shares on the open market. Not a grant or an option exercise. Their past buys: 4 of 8 checked quarters beat the typical stock 6 months later.
Immuneering (IMRX) Director Peter Feinberg bought $87K
20,000 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 5 checked quarters beat the typical stock 6 months later.
Jefferson Capital (JCAP) Officer David Burton sold $7.89M
Not marked as a planned 10b5-1 sale. Sold 10% of the shares they held directly. Still holds 3.39M shares.
Amprius Technologies (AMPX) Director Kang Sun sold $5.11M
Not marked as a planned 10b5-1 sale. Sold 27% of the shares they held directly. Still holds 1.4M shares.
Omeros (OMER) VP David Borges sold $751K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 10 more real buys
Show 30 more real sales
13F season
Holdings as of Dec 31, 2025 are due Feb 17
320 funds have filed so far. 81 filed for the quarter before.
Biggest real insider buys this week
Open-market buys by officers and directors, filed in the 7 days up to Jan 14.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.